F
Acorda Therapeutics, Inc.
ACORQ
OTC PK
E
Sell
5/14/2024Downgrade
Acorda Therapeutics, Inc. () was downgraded to E+ from D- on 5/14/2024 due to a decline in the total return index and volatility index.
Acorda Therapeutics, Inc. () was downgraded to E+ from D- on 5/14/2024 due to a decline in the total return index and volatility index.
D
Sell
4/29/2024Upgraded
Acorda Therapeutics, Inc. () was upgraded to D- from E+ on 4/29/2024 due to an increase in the volatility index.
Acorda Therapeutics, Inc. () was upgraded to D- from E+ on 4/29/2024 due to an increase in the volatility index.
E
Sell
4/11/2024Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 4/11/2024 due to a major decline in the solvency index, growth index and volatility index. Earnings per share declined from -$7.16 to -$175.3309, operating cash flow declined 139.67% from $7.61M to -$3.02M, and the quick ratio declined from 0.96 to 0.21.
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 4/11/2024 due to a major decline in the solvency index, growth index and volatility index. Earnings per share declined from -$7.16 to -$175.3309, operating cash flow declined 139.67% from $7.61M to -$3.02M, and the quick ratio declined from 0.96 to 0.21.
D
Sell
4/1/2024Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 4/1/2024 due to an increase in the volatility index and total return index.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 4/1/2024 due to an increase in the volatility index and total return index.
E
Sell
3/12/2024Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 3/12/2024 due to a decline in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 3/12/2024 due to a decline in the volatility index.
D
Sell
2/15/2024Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 2/15/2024 due to an increase in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 2/15/2024 due to an increase in the volatility index.
E
Sell
1/30/2024Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 1/30/2024 due to a decline in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 1/30/2024 due to a decline in the volatility index.
D
Sell
1/4/2024Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 1/4/2024 due to an increase in the volatility index and total return index.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 1/4/2024 due to an increase in the volatility index and total return index.
E
Sell
12/20/2023Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 12/20/2023 due to a decline in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 12/20/2023 due to a decline in the volatility index.
D
Sell
12/4/2023Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 12/4/2023 due to an increase in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 12/4/2023 due to an increase in the volatility index.
E
Sell
11/16/2023Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 11/16/2023 due to a decline in the growth index, volatility index and total return index. EBIT declined 73.29% from -$4.46M to -$7.72M, and total revenue declined 6.6% from $29.68M to $27.72M.
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 11/16/2023 due to a decline in the growth index, volatility index and total return index. EBIT declined 73.29% from -$4.46M to -$7.72M, and total revenue declined 6.6% from $29.68M to $27.72M.
D
Sell
11/10/2023Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 11/10/2023 due to an increase in the volatility index and growth index.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 11/10/2023 due to an increase in the volatility index and growth index.
E
Sell
10/24/2023Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 10/24/2023 due to a decline in the volatility index and total return index.
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 10/24/2023 due to a decline in the volatility index and total return index.
D
Sell
10/6/2023Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 10/6/2023 due to an increase in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 10/6/2023 due to an increase in the volatility index.
E
Sell
9/19/2023Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 9/19/2023 due to a decline in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 9/19/2023 due to a decline in the volatility index.
D
Sell
8/31/2023Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 8/31/2023 due to an increase in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 8/31/2023 due to an increase in the volatility index.
E
Sell
8/14/2023Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 8/14/2023 due to a decline in the volatility index and valuation index.
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 8/14/2023 due to a decline in the volatility index and valuation index.
D
Sell
7/27/2023Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 7/27/2023 due to an increase in the volatility index and total return index.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 7/27/2023 due to an increase in the volatility index and total return index.
E
Sell
7/10/2023Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 7/10/2023 due to a decline in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 7/10/2023 due to a decline in the volatility index.
D
Sell
6/21/2023Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 6/21/2023 due to an increase in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 6/21/2023 due to an increase in the volatility index.
E
Sell
6/5/2023Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 6/5/2023 due to a significant decline in the growth index, volatility index and total return index. EBIT declined 391.1% from $4.32M to -$12.57M, earnings per share declined from $8.8254 to -$13.8253, and operating cash flow declined 177.41% from $9.07M to -$7.02M.
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 6/5/2023 due to a significant decline in the growth index, volatility index and total return index. EBIT declined 391.1% from $4.32M to -$12.57M, earnings per share declined from $8.8254 to -$13.8253, and operating cash flow declined 177.41% from $9.07M to -$7.02M.
D
Sell
5/30/2023Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 5/30/2023 due to an increase in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 5/30/2023 due to an increase in the volatility index.
E
Sell
5/10/2023Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 5/10/2023 due to a decline in the volatility index and total return index.
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 5/10/2023 due to a decline in the volatility index and total return index.
D
Sell
4/24/2023Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 4/24/2023 due to an increase in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 4/24/2023 due to an increase in the volatility index.
E
Sell
4/4/2023Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 4/4/2023 due to a decline in the volatility index and total return index.
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 4/4/2023 due to a decline in the volatility index and total return index.
D
Sell
3/17/2023Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 3/17/2023 due to an increase in the volatility index, solvency index and total return index. The quick ratio increased from 0.84 to 1.35, and debt to equity declined from 2.5 to 1.8.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 3/17/2023 due to an increase in the volatility index, solvency index and total return index. The quick ratio increased from 0.84 to 1.35, and debt to equity declined from 2.5 to 1.8.
E
Sell
3/14/2023Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
D
Sell
2/9/2023Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Acorda Therapeutics, Inc. (ACORQ) was downgraded to E+ from D on 02/08/2023.
Acorda Therapeutics, Inc. (ACORQ) was downgraded to E+ from D on 02/08/2023.
D
Sell
10/20/2022Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D from D- on 10/20/2022 due to an increase in the volatility index and total return index.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D from D- on 10/20/2022 due to an increase in the volatility index and total return index.
D
Sell
10/4/2022Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to D- from D on 10/4/2022 due to a decline in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was downgraded to D- from D on 10/4/2022 due to a decline in the volatility index.
D
Sell
9/16/2022Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D from D- on 9/16/2022 due to an increase in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D from D- on 9/16/2022 due to an increase in the volatility index.
D
Sell
8/29/2022Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to D- from D on 8/29/2022 due to a decline in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was downgraded to D- from D on 8/29/2022 due to a decline in the volatility index.
D
Sell
8/12/2022Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D from D- on 8/12/2022 due to a noticeable increase in the growth index. Total revenue increased 37.8% from $22.53M to $31.05M, and EBIT increased 12.79% from -$19.53M to -$17.03M.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D from D- on 8/12/2022 due to a noticeable increase in the growth index. Total revenue increased 37.8% from $22.53M to $31.05M, and EBIT increased 12.79% from -$19.53M to -$17.03M.
D
Sell
5/16/2022Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 5/16/2022 due to an increase in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
D
Sell
5/4/2022Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/21/2022Upgraded
Acorda Therapeutics, Inc. (ACORQ) was upgraded to D from E+ on 04/21/2022.
Acorda Therapeutics, Inc. (ACORQ) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index and total return index.
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index and total return index.
D
Sell
3/21/2022Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D from D- on 3/21/2022 due to a significant increase in the growth index, solvency index and volatility index. Operating cash flow increased 135.95% from -$9.01M to $3.24M, EBIT increased 82.47% from -$18.89M to -$3.31M, and the quick ratio increased from 0.73 to 1.16.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D from D- on 3/21/2022 due to a significant increase in the growth index, solvency index and volatility index. Operating cash flow increased 135.95% from -$9.01M to $3.24M, EBIT increased 82.47% from -$18.89M to -$3.31M, and the quick ratio increased from 0.73 to 1.16.
D
Sell
11/17/2021Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to D- from D on 11/17/2021 due to a significant decline in the growth index, volatility index and total return index. Earnings per share declined from -$2.29 to -$2.432, operating cash flow declined 3.73% from -$8.69M to -$9.01M, and total revenue declined 1.04% from $31.79M to $31.46M.
Acorda Therapeutics, Inc. (ACOR) was downgraded to D- from D on 11/17/2021 due to a significant decline in the growth index, volatility index and total return index. Earnings per share declined from -$2.29 to -$2.432, operating cash flow declined 3.73% from -$8.69M to -$9.01M, and total revenue declined 1.04% from $31.79M to $31.46M.
D
Sell
11/9/2021Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index.
E
Sell
11/8/2021Downgrade
Acorda Therapeutics, Inc. (ACORQ) was downgraded to E+ from D on 11/08/2021.
Acorda Therapeutics, Inc. (ACORQ) was downgraded to E+ from D on 11/08/2021.
D
Sell
5/21/2021Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D from D- on 5/21/2021 due to a noticeable increase in the growth index and valuation index. Earnings per share increased from -$9.8235 to -$3.5323.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D from D- on 5/21/2021 due to a noticeable increase in the growth index and valuation index. Earnings per share increased from -$9.8235 to -$3.5323.
D
Sell
3/18/2021Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to D- from D on 3/18/2021 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from $0.3186 to -$9.8235, net income declined 1,230.37% from $7.35M to -$83.05M, and EBIT declined 38.55% from -$12.44M to -$17.23M.
Acorda Therapeutics, Inc. (ACOR) was downgraded to D- from D on 3/18/2021 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from $0.3186 to -$9.8235, net income declined 1,230.37% from $7.35M to -$83.05M, and EBIT declined 38.55% from -$12.44M to -$17.23M.
D
Sell
11/16/2020Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D from E+ on 11/16/2020 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 142.17% from -$17.42M to $7.35M, earnings per share increased from -$0.37 to $0.0531, and operating cash flow increased 86.01% from -$20.77M to -$2.91M.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D from E+ on 11/16/2020 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 142.17% from -$17.42M to $7.35M, earnings per share increased from -$0.37 to $0.0531, and operating cash flow increased 86.01% from -$20.77M to -$2.91M.
E
Sell
5/8/2020Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 5/8/2020 due to a noticeable decline in the growth index, solvency index and efficiency index. Operating cash flow declined 239.3% from -$11.43M to -$38.78M, EBIT declined 175.46% from -$11.71M to -$32.25M, and earnings per share declined from $1.3735 to -$0.14.
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 5/8/2020 due to a noticeable decline in the growth index, solvency index and efficiency index. Operating cash flow declined 239.3% from -$11.43M to -$38.78M, EBIT declined 175.46% from -$11.71M to -$32.25M, and earnings per share declined from $1.3735 to -$0.14.
D
Sell
3/3/2020Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 3/3/2020 due to a large increase in the growth index, volatility index and solvency index. Earnings per share increased from -$5.55 to $1.3735, EBIT increased 64.23% from -$32.73M to -$11.71M, and operating cash flow increased 53.07% from -$24.35M to -$11.43M.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 3/3/2020 due to a large increase in the growth index, volatility index and solvency index. Earnings per share increased from -$5.55 to $1.3735, EBIT increased 64.23% from -$32.73M to -$11.71M, and operating cash flow increased 53.07% from -$24.35M to -$11.43M.
E
Sell
2/28/2020Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 2/28/2020 due to a decline in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D- on 2/28/2020 due to a decline in the volatility index.
D
Sell
2/12/2020Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 2/12/2020 due to an increase in the volatility index and total return index.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D- from E+ on 2/12/2020 due to an increase in the volatility index and total return index.
E
Sell
11/12/2019Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D on 11/12/2019 due to a significant decline in the total return index, growth index and volatility index. Earnings per share declined from -$0.58 to -$5.55, operating cash flow declined 63.53% from -$14.89M to -$24.35M, and total revenue declined 4.66% from $50.05M to $47.72M.
Acorda Therapeutics, Inc. (ACOR) was downgraded to E+ from D on 11/12/2019 due to a significant decline in the total return index, growth index and volatility index. Earnings per share declined from -$0.58 to -$5.55, operating cash flow declined 63.53% from -$14.89M to -$24.35M, and total revenue declined 4.66% from $50.05M to $47.72M.
D
Sell
9/11/2018Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to D from D+ on 9/11/2018 due to a large decline in the growth index and valuation index.
Acorda Therapeutics, Inc. (ACOR) was downgraded to D from D+ on 9/11/2018 due to a large decline in the growth index and valuation index.
D
Sell
5/11/2018Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D+ from D on 5/11/2018 due to a major increase in the growth index, valuation index and volatility index. Earnings per share increased from -$3.7027 to -$0.1762.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D+ from D on 5/11/2018 due to a major increase in the growth index, valuation index and volatility index. Earnings per share increased from -$3.7027 to -$0.1762.
D
Sell
11/9/2017Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to D from D+ on 11/9/2017 due to a large decline in the growth index, efficiency index and solvency index. Net income declined 207.41% from -$8.2M to -$25.2M, earnings per share declined from -$0.18 to -$0.55, and debt to equity increased from 0.48 to 0.49.
Acorda Therapeutics, Inc. (ACOR) was downgraded to D from D+ on 11/9/2017 due to a large decline in the growth index, efficiency index and solvency index. Net income declined 207.41% from -$8.2M to -$25.2M, earnings per share declined from -$0.18 to -$0.55, and debt to equity increased from 0.48 to 0.49.
D
Sell
10/27/2017Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to D+ from D on 10/27/2017 due to a noticeable increase in the growth index, total return index and volatility index. EBIT increased 531.09% from -$3.87M to $16.7M, operating cash flow increased 140.63% from -$25.4M to $10.32M, and earnings per share increased from -$0.4127 to -$0.18.
Acorda Therapeutics, Inc. (ACOR) was upgraded to D+ from D on 10/27/2017 due to a noticeable increase in the growth index, total return index and volatility index. EBIT increased 531.09% from -$3.87M to $16.7M, operating cash flow increased 140.63% from -$25.4M to $10.32M, and earnings per share increased from -$0.4127 to -$0.18.
D
Sell
8/5/2016Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to D from D+ on 8/5/2016 due to a large decline in the efficiency index, growth index and total return index. Net income declined 3,415.19% from -$520 to -$18.28M, earnings per share declined from -$0.0116 to -$0.4032, and operating cash flow declined 242.6% from $6.7M to -$9.55M.
Acorda Therapeutics, Inc. (ACOR) was downgraded to D from D+ on 8/5/2016 due to a large decline in the efficiency index, growth index and total return index. Net income declined 3,415.19% from -$520 to -$18.28M, earnings per share declined from -$0.0116 to -$0.4032, and operating cash flow declined 242.6% from $6.7M to -$9.55M.
D
Sell
4/28/2016Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to D+ from C- on 4/28/2016 due to a noticeable decline in the total return index, volatility index and solvency index.
Acorda Therapeutics, Inc. (ACOR) was downgraded to D+ from C- on 4/28/2016 due to a noticeable decline in the total return index, volatility index and solvency index.
C
Hold
3/11/2016Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to C- from C on 3/11/2016 due to a major decline in the volatility index, efficiency index and valuation index.
Acorda Therapeutics, Inc. (ACOR) was downgraded to C- from C on 3/11/2016 due to a major decline in the volatility index, efficiency index and valuation index.
C
Hold
5/11/2015Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to C from C+ on 5/11/2015 due to a large decline in the volatility index, growth index and total return index. Earnings per share declined from $0.0079 to -$0.0734, operating cash flow declined 168.07% from $13.59M to -$9.25M, and EBIT declined 88.09% from $15.46M to $1.84M.
Acorda Therapeutics, Inc. (ACOR) was downgraded to C from C+ on 5/11/2015 due to a large decline in the volatility index, growth index and total return index. Earnings per share declined from $0.0079 to -$0.0734, operating cash flow declined 168.07% from $13.59M to -$9.25M, and EBIT declined 88.09% from $15.46M to $1.84M.
C
Hold
3/2/2015Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to C+ from B- on 3/2/2015 due to a significant decline in the growth index, efficiency index and solvency index. Net income declined 97.24% from $11.95M to $330, earnings per share declined from $0.28 to $0.0079, and operating cash flow declined 64.63% from $38.42M to $13.59M.
Acorda Therapeutics, Inc. (ACOR) was downgraded to C+ from B- on 3/2/2015 due to a significant decline in the growth index, efficiency index and solvency index. Net income declined 97.24% from $11.95M to $330, earnings per share declined from $0.28 to $0.0079, and operating cash flow declined 64.63% from $38.42M to $13.59M.
B
Buy
11/24/2014Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to B- from C+ on 11/24/2014 due to an increase in the volatility index, efficiency index and solvency index. Net income increased 155.13% from $4.69M to $11.95M, the quick ratio increased from 6.69 to 7.84, and debt to equity declined from 0.57 to 0.55.
Acorda Therapeutics, Inc. (ACOR) was upgraded to B- from C+ on 11/24/2014 due to an increase in the volatility index, efficiency index and solvency index. Net income increased 155.13% from $4.69M to $11.95M, the quick ratio increased from 6.69 to 7.84, and debt to equity declined from 0.57 to 0.55.
C
Hold
10/22/2014Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to C+ from B- on 10/22/2014 due to a decline in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was downgraded to C+ from B- on 10/22/2014 due to a decline in the volatility index.
B
Buy
10/7/2014Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to B- from C+ on 10/7/2014 due to an increase in the volatility index and total return index.
Acorda Therapeutics, Inc. (ACOR) was upgraded to B- from C+ on 10/7/2014 due to an increase in the volatility index and total return index.
C
Hold
9/22/2014Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to C+ from B- on 9/22/2014 due to a decline in the volatility index.
Acorda Therapeutics, Inc. (ACOR) was downgraded to C+ from B- on 9/22/2014 due to a decline in the volatility index.
B
Buy
8/26/2014Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to B- from C+ on 8/26/2014 due to a major increase in the growth index, valuation index and efficiency index. Net income increased 566.43% from $703 to $4.69M, earnings per share increased from $0.0172 to $0.11, and operating cash flow increased 334.54% from $4.31M to $18.71M.
Acorda Therapeutics, Inc. (ACOR) was upgraded to B- from C+ on 8/26/2014 due to a major increase in the growth index, valuation index and efficiency index. Net income increased 566.43% from $703 to $4.69M, earnings per share increased from $0.0172 to $0.11, and operating cash flow increased 334.54% from $4.31M to $18.71M.
C
Hold
3/7/2014Downgrade
Acorda Therapeutics, Inc. (ACOR) was downgraded to C+ from B+ on 3/7/2014 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.18 to $0.1394, net income declined 17.2% from $7.48M to $6.19M, and operating cash flow declined 1.3% from $19.44M to $19.19M.
Acorda Therapeutics, Inc. (ACOR) was downgraded to C+ from B+ on 3/7/2014 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.18 to $0.1394, net income declined 17.2% from $7.48M to $6.19M, and operating cash flow declined 1.3% from $19.44M to $19.19M.
B
Buy
3/3/2014Upgraded
Acorda Therapeutics, Inc. (ACOR) was upgraded to B+ from B on 3/3/2014 due to an increase in stability and total return.
Acorda Therapeutics, Inc. (ACOR) was upgraded to B+ from B on 3/3/2014 due to an increase in stability and total return.
